|   | 1. | All      references to “ARCH” in the Agreement shall be changed to      “University”. |
|--------|----|---------------------------------------------------------------------------------------------------------------|

|   | 2. | Paragraph      3.A(1)(1) will be deleted in its entirety and replaced with the following:      “$* at the time of the filing in the United States by Licensee or any      Sublicensee of an NDA on a Licensed Product (such payment referred to as      an “NDA Fee”), provided a Licensed Product utilizes the Complimentary      Invention.  If Complimentary Invention is not utilized in an NDA      on a Licensed Product, NDA” |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 3. | Paragraph      3.B (2) will be amended to read as follows: “In the event that Licensee or      its Sublicensee enters into a license agreement with any third party with      respect to intellectual property rights which are necessary or useful for      Licensee’s practice of the Licensed Patents or the manufacture, use,      import and/or sale of any Licensed Product, Licensee and Sublicensees may      offset any payments made in accordance with such license agreements      against any amounts owed Licensors pursuant to Paragraph 3B herein, on a      country-by-country basis, up to a maximum of * of the amounts due under      Paragraph 3B.  Any such amounts which are not offset in any      quarter may be carried forward untilapplied.” |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4. | Paragraph      4.A(1) shall be amended to include “Fulbright and Jaworski;” after the      word “Borum” in line 3. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5. | Paragraph      5.A shall be amended to include |
|--------|----|------------------------------------------------|

|   | “Resources      will be allocated to support this technology in conjunction with GenVec’s      ongoing program to advance TNFerade as a product      candidate.  These resources will take several forms, including      direct research funding of chemoinduction research in the laboratory of      Ralph Weichselbaum, and internal work at GenVec to confirm hypotheses      surrounding the chemoinduction work.  Upon generation of      appropriate clinical data surrounding this technology and gaining required      approvals to pursue clinical studies in this area, GenVec anticipates      applying further resources to the technology, leading to development of      safety and efficacy packages.” |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6. | Paragraph      5.B. shall be amended as follows: “For the Complimentary Invention and      within thirty (30) days of June 30th      during the term of this Agreement, Licensee shall make a written report to      UCTech, in such detail as UCTech may reasonably request, covering the      preceding twelve (12) months and describing the progress of Licensee      towards achieving the development and commercialization of Licensed      Products relating to the Complimentary Invention.  Licensee      agrees to immediately notify UCTech in writing when commercial products      are first sold and when Licensee’s obligation to make running Royalty      payments begins. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7. | Paragraph      11.E. is amended to read: |
|--------|----|------------------------------------------|

|   | If      to UCTech: | UCTech, |
|--------|--------------------|---------|

|   | The      University of Chicago |
|--------|--------------------------------|

|   | 5640      South Ellis, Suite 405 |
|--------|----------------------------------|

|   | Chicago,      IL 60637 |
|--------|------------------------|

|   | Attention:      Director of Technology Transfer |
|--------|-------------------------------------------------|

|   | If      to GenVec: | GenVec      Inc. |
|--------|--------------------|------------------|

|   | 65      West Watkins Mill Rd. |
|--------|-------------------------------|

|   | Gaithersburg,      MD 20878 |
|--------|-----------------------------|

|   | Attention:      President |
|--------|---------------------------|

|   | With      a copy to: Vice President, CorporateDevelopment |
|--------|-----------------------------------------------------------|

----

|   | 8. | Paragraph      11.H. shall be deleted in itsentirety. |
|--------|----|-------------------------------------------------------|

| UCTech                               |      | GenVec      Corporation                 |
|--------------------------------------|-----------|-----------------------------------------|
|                                 |      |                                    |
| By:                                  |      |                                    | By: |   |
|                                 |      |                                    |
| Alan      E. P. Thomas               |      | Thomas      Smart                       |
|                                 |      |                                    |
| Director      of Technology Transfer |      | Senior      Vice President of Corporate |
| Date:                                | 2/13/2002 |                                    | Development |
|                                 |      |                                    |
|                                 |      | Date:                                   | 2/27/2002 |

| DFCI                                         |      |
|----------------------------------------------|-----------|
|                                         |      |
| By:                                          |      |   |
| Ruth      Emyanitoff                         |      |
|                                         |      |
| Director,      Office of Technology Transfer |      |
| Date:                                        | 2/21/2002 |   |

----